# Shinezy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shinezy

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.shinehe.com
- Latest round: Series B (Jan 20, 2025)
- Investors on record: 5

## About

Established in 2010 and based in Hangzhou, China, Shinezy is a company that manufactures critical precision components and medical endoscopy consumables. It is a company that manufactures critical precision components and medical endoscopy consumables. The company is headquartered in Hangzhou, with R&D centers in Shenzhen and Hangzhou, and production facilities in Hangzhou, Lin'an and Dongguan. As of 2024, it owns more than 40 invention patents and has produced more than 10 million pieces of OEM/ODM devices. The company has passed the ISO9001:2015 system, ISO13485:2016 system and intellectual property certification, and has been recognized as a national high-tech enterprise. In January 2025, it closed a series B+ funding.

Shinezy is mainly engaged in the production and sales of minimally invasive medical devices. Its products include rigid endoscopes, flexible endoscopes, endoscopic surgical instruments, minimally invasive surgical instruments, etc.

Shinezy generates revenue by providing precision components production, customized development, and Contract Development and Manufacturing Organization (CDMO) services to the medical industry.

## Funding rounds

- Series B, Jan 20, 2025 — Qiming Venture Partners, Sanmei Capital, Baifu Capital
- Series B, Jul 8, 2024 — Qiming Venture Partners, TTGG Ventures
- Series A, Mar 28, 2023 — Wuchan Zhongda Group Investment

## Investors

- Wuchan Zhongda Group Investment (https://capitalatlas.ai/funds/wuchan-zhongda-group-investment) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series B
- Sanmei Capital (https://capitalatlas.ai/funds/sanmei-capital) — Series B
- Baifu Capital (https://capitalatlas.ai/funds/baifu-capital) — Series B